Over the last decade there has been a significant increase in interest in the clinical use of positron-emitting tracers. [18F]-FDG with its 109.8-minute half-life lends itself to use not only at sites close to a cyclotron and chemistry facility, but also allows transportation to scanners at sites remote from the cyclotron. It is the most commonly used tracer in clinical PET at present and the combination of these two factors means that hospitals are looking more and more at the possibility of introducing this radio-pharmaceutical for use within existing departments. However, clinical units usually require high throughput (compared with research facilities) and this inevitably means increased numbers of scans and an increased radiation burden in the department.
Was this article helpful?